by: Patrick Campbell
While anti-VEGF therapies have cemented their place in the treatment of ophthalmic conditions, including age-related macular degeneration (AMD), there is still an onus on reduce treatment burden when developing new treatments.
While aflibercept has solidified its role as the standard, first-line treatment for AMD among most retina specialists for more than a decade, there are multiple treatments seeking to replace aflibercept in that role.
Therapy pipelines have revealed many new therapies, some of which have received approval and others that have moved into phase 3 clinical trials. In recent years, we have seen the approval of a therapy that drastically reduces the frequency of injections and a number of potential therapies seeking to do the same—or even eliminate the need for injections.
Many ophthalmologists are hopeful faricimab will continue to show promise for the treatment of a multitude of ophthalmic conditions. Meanwhile, a phase 3 trial for the Port Delivery System with Ranibizumab is sure to be one of the most anticipated studies in recent years.
To learn more about which therapies retina specialists are most excited about, HCPLive® recently sat down with Daniel Kiernan, MD, a vitreoretinal surgeon with the Ophthalmic Consultants of Long Island, to discuss the topic.
Source: MD Magazine